Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q6P3W7
UPID:
SCYL2_HUMAN
Alternative names:
Coated vesicle-associated kinase of 104 kDa
Alternative UPACC:
Q6P3W7; A8KAB5; Q96EF4; Q96ST4; Q9H7V5; Q9NVH3; Q9P2I7
Background:
SCY1-like protein 2, also known as the Coated vesicle-associated kinase of 104 kDa, plays a pivotal role in cellular processes. It is involved in the AP2-containing clathrin coat regulation, crucial for clathrin-dependent trafficking at the plasma membrane, TGN, and endosomal system. Additionally, it potentially acts as a serine/threonine-protein kinase, influencing the beta2-subunit of the plasma membrane adapter complex AP2 and other proteins. Its role in regulating excitatory receptors at synapses underscores its importance in neuronal function, signaling, and brain development.
Therapeutic significance:
SCY1-like protein 2's involvement in Arthrogryposis multiplex congenita 4, a severe developmental condition, highlights its therapeutic significance. Understanding its role could pave the way for innovative treatments for this and potentially other neurological disorders.